Sales grew 31% to $609 million during the first quarter of 2021 (end-April 3). Sales were $465 million during the first quarter of 2020. Adjusted free cash flow increased 60% to $193 million in the first quarter of 2021, compared to $121 million during the same period the year before, according to the company.

"There is much to be pleased about with our first quarter results, driven by strong growth across each of our major end markets, with pharma leading the way," said Udit Batra, PhD, president and CEO of Waters. "Thanks to solid execution and instrument sales growing in double-digits, we saw revenue increases across every region, with China's sales more than doubling."

Waters, Genovis team up on automated CQA characterization
Waters and Genovis are working together to develop and market routine biopharmaceutical characterization workflows of critical quality attributes (CQAs)...

Waters launches MAM workflow for protein-based drug analysis
Waters has introduced a new peptide multiattribute method (MAM) workflow for its BioAccord liquid chromatography-mass spectrometry system.

Waters launches new small molecule mass spectrometer
Waters has released its new time-of-flight mass spectrometer, the Acquity RDa Detector, for small molecule analysis.